BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease.

BCMA指导的嵌合抗原受体T细胞疗法和双特异性T细胞参与者正在转向多发性骨髓瘤的早期治疗方案。此外，在首次或随后复发时与BCMA靶向抗体-药物偶联物belantamab-mafodotin联合治疗有可能提高该病患者的生存率。

This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex..

越来越多的治疗选择使得治疗选择和测序变得越来越复杂。。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springer link上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

Fig. 1: Evolving first-line and second-line treatment options for MM.

图1：发展MM的一线和二线治疗选择。

Referencesvan de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410–427 (2021).Article

参考文献Van de Donk，N.W.C.J.，Pawlyn，C。＆Yong，K.L。多发性骨髓瘤。柳叶刀397410-427（2021）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2405090 (2024).Article

Hungria，V.等人。Belantamab镁氟丁、硼替佐米和地塞米松治疗多发性骨髓瘤。N.Engl。医学杂志。https://doi.org/10.1056/NEJMoa2405090(2024).文章

PubMed

PubMed

Google Scholar

谷歌学者

Dimopoulos, M. A. et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2403407 (2024).Article

Dimopoulos，M.A.等人。Belantamab、mafodotin、泊马度胺和地塞米松在多发性骨髓瘤中的应用。N.Engl。医学杂志。https://doi.org/10.1056/NEJMoa2403407(2024).文章

PubMed

PubMed

Google Scholar

谷歌学者

Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207–221 (2020).Article

Lonial，S。等人。Belantamab-mafodotin治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂，随机，开放标签，2期研究。柳叶刀Oncol。21207-221（2020）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Lonial, S. et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 127, 4198–4212 (2021).Article

Lonial，S.等人。复发或难治性多发性骨髓瘤患者单药belantamab-mafodotin的长期疗效：关键性DREAMM-2研究的13个月随访。。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Dimopoulos, M. A. et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 10, e801–e812 (2023).Article .

。柳叶刀血液。10，e801–e812（2023）。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002–1014 (2023).Article

Rodriguez-Otero，P。等人在复发和难治性多发性骨髓瘤中使用cel或标准方案。N、 英语。J、 医学3881002-1014（2023）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335–347 (2023).Article

San Miguel，J.等。来那度胺难治性多发性骨髓瘤的Cilta cel或标准治疗。N、 英语。J、 医学389335-347（2023）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

van de Donk, N. W. C. J. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142–158 (2023).Article

van de Donk，N.W.C.J。＆Zweegman，S。T细胞参与癌症中的双特异性抗体。柳叶刀402142-158（2023）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Lin, Y. et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.

Lin，Y.等。复发和难治性多发性骨髓瘤临床实践中嵌合抗原受体T细胞治疗管理和反应评估的共识指南和建议：国际骨髓瘤工作组免疫治疗委员会的报告。

Lancet Oncol. https://doi.org/10.1016/S1470-2045(24)00094-9 (2024).Article .

《柳叶刀肿瘤学》。https://doi.org/10.1016/S1470-2045(24)00094-9 (2024).第条。

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAcknowledgementsThe authors thank C. L. B. M. Korst for help with designing Fig. 1.Author informationAuthors and AffiliationsDepartment of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NetherlandsNiels W. C. J. van de Donk & Sonja ZweegmanCancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, NetherlandsNiels W.

下载参考文献致谢作者感谢C.L.B.M.Korst为设计提供的帮助。图1.作者信息作者和所属机构阿姆斯特丹大学血液学系，荷兰阿姆斯特丹大学，阿姆斯特丹，荷兰斯奈尔斯W.C.J.van de Donk＆Sonja ZweegmanCancer Biology and Immunology，阿姆斯特丹癌症中心，阿姆斯特丹，荷兰斯奈尔斯W。

C. J. van de Donk & Sonja ZweegmanAuthorsNiels W. C. J. van de DonkView author publicationsYou can also search for this author in.

Niels W.C.J.van de Donk查看作者出版物您也可以在中搜索此作者。

PubMed Google ScholarSonja ZweegmanView author publicationsYou can also search for this author in

PubMed Google ScholarSonja ZweegmanView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Niels W. C. J. van de Donk.Ethics declarations

Niels W.C.J.van de Donk。

Competing interests

相互竞争的利益

N.W.C.J.v.d.D. has received research support via his institution from Amgen, Bristol Myers Squibb (BMS), Celgene, Cellectis, Janssen and Novartis, and serves on advisory boards for AbbVie, Adaptive Biotech, Amgen, Bayer, BMS, Celgene, Janssen, Kite Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Servier and Takeda.

N.W.C.J.v.d.d.通过其所在机构获得了安进、百时美施贵宝（BMS）、新基、Cellectis、杨森和诺华的研究支持，并担任艾伯维、Adaptive Biotech、安进、拜耳、BMS、Celgene、杨森、Kite Pharma、默克、诺华、辉瑞、罗氏、赛诺菲、施维雅和武田的顾问委员会成员。

S.Z. has received research support via her institution from Janssen and Takeda, and serves on advisory boards for BMS, GSK, Janssen, Oncopeptides, Sanofi and Takeda..

S、 Z.通过她的机构获得了杨森和武田的研究支持，并在BMS，GSK，杨森，Oncopeptides，赛诺菲和武田的咨询委员会任职。。

Rights and permissionsReprints and permissionsAbout this articleCite this articlevan de Donk, N.W.C.J., Zweegman, S. BCMA-directed therapy for early relapsed and/or refractory multiple myeloma.

权利和许可本文引用本文Van de Donk，N.W.C.J.，Zweegman，S。BCMA指导治疗早期复发和/或难治性多发性骨髓瘤。

Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00927-6Download citationPublished: 19 July 2024DOI: https://doi.org/10.1038/s41571-024-00927-6Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Clin Oncol（2024）。https://doi.org/10.1038/s41571-024-00927-6Download引文发布日期：2024年7月19日OI：https://doi.org/10.1038/s41571-024-00927-6Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供

Subjects

主题

Combination drug therapyDrug developmentMyelomaRandomized controlled trialsTargeted therapies

联合药物治疗药物开发骨髓随机对照试验靶向治疗